Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Novo Nordisk Skeptic Finally Upgrades Stock
Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...
After years of calling obesity drug stocks overhyped, a top analyst now sees Novo Nordisk as a big opportunity.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback